** Shares of cancer drugmaker Exelixis EXEL.O rise 5.6% to $39 premarket
** Co late on Tuesday raised 2025 rev. forecast to between $2.25 billion and $2.35 billion, compared with prior view of between $2.15 billion and $2.25 billion
** Co posted Q1 total rev. of $555.4 million, beating analysts' estimate of $498.2 million - data compiled by LSEG
** Co posted Q1 adj. profit of 62 cents per share vs estimates of 36 cents per share on sales of its cancer drug, Cabometyx
** As of last close, stock up 11% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。